Drugs / Raludotatug Deruxtecan
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04707248 | Dec 2020 → Dec 2026 expected | ovarian neoplasm, renal cell carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06843447 | Apr 2025 → Mar 2029 expected | ovarian carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06780085 | May 2025 → Mar 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06864169 | Apr 2025 → Aug 2026 overdue | digestive system cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06660654 | Jan 2025 → Dec 2029 expected | metastatic neoplasm | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06161025 | Feb 2024 → Feb 2028 expected | — | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07791732 | Oct 2026 → Jul 2029 expected | fallopian tube cancer, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07776691 | Sep 2026 → Mar 2032 expected | fallopian tube cancer, ovarian cancer, peritoneum cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-13 | Merck Sharp & Dohme LLC | Regulatory Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy merck.com ↗ |
| 2025-09-07 | Merck Sharp & Dohme LLC | Results Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial merck.com ↗
Results from the IDeate-Lung01 Phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). |
| 2024-09-07 | Merck Sharp & Dohme LLC | Results Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial merck.com ↗
Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continues to demonstrate promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). |
All press releases naming this drug 6 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Raludotatug Deruxtecan | “A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants...” NCT07776691 ↗7“A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)” NCT07791732 ↗ “This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).” NCT04707248 ↗ “A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer” NCT06161025 ↗ |
| Known as | DS-6000a | “This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).” NCT04707248 ↗ |
| Known as | MK-5909 | “A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants...” NCT07776691 ↗ |
| Known as | R-DXd | “A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants...” NCT07776691 ↗3“A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)” NCT07791732 ↗ “The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC).” NCT06864169 ↗ |
| Action | Deplete | “An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells.” NCT06780085 ↗ |
| Modality | Other / unclassified | “R-DXd is an antibody drug conjugate” NCT04707248 ↗ |
| Route | Intravenous | “Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1” NCT04707248 ↗ |
| Target | CDH6 | “R-DXd is an antibody drug conjugate that specifically binds to CDH6 on the cell surface of target cells” NCT04707248 ↗ |